Patents by Inventor Robert Fletterick

Robert Fletterick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 9782399
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 10, 2017
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Regents of the University of California, The Board of Regents of The University of Texas System
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20160151350
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: December 1, 2015
    Publication date: June 2, 2016
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 9233973
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: January 12, 2016
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Regents of the University of California, a California Corporation, Board of Regents, The University of Texas System
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20150011516
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather A. Balsiger, Robert Fletterick
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20120283215
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: September 14, 2010
    Publication date: November 8, 2012
    Applicants: The Regents of the University of California, a California Corporation, University of Texas at El Paso, Health and Human Services
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather Balsiger, Robert Fletterick
  • Inhibitors for androgen antagonist refractory prostate cancer
    Publication number: 20070087352
    Abstract: The present invention relates to methods and antagonist compounds for modulating androgen receptor activity. The invention includes a method for identifying molecules that bind to a coactivator binding site of a receptor in the androgen receptor family. Also included is a cocrystal of an androgen receptor ligand binding domain complexed with a ligand and a coactivator. The invention further includes a method for inhibiting androgen receptor activity in a mammal, thereby facilitating treatment of diseases such as prostate cancer.
    Type: Application
    Filed: November 6, 2003
    Publication date: April 19, 2007
    Inventors: Robert Fletterick, Eva Estebanez-Perpina, Eugene Hur, Samuel Pfaff, Benjamin Buehrer
  • Nuclear receptor ligands and ligand binding domains
    Publication number: 20070027215
    Abstract: The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as “TR”). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.
    Type: Application
    Filed: April 16, 2004
    Publication date: February 1, 2007
    Applicant: The Regents of the University of California
    Inventors: John Baxter, Robert Fletterick, Peter Kushner
  • Modulating nuclear receptor coactivator binding
    Publication number: 20060149521
    Abstract: The present invention comprises cocrystal of a nuclear receptor comprising a molecule bound to the coactivator binding site of said nuclear receptor. The present invention further comprises a machine-readable data storage medium encoded with machine readable data corresponding to the structure coordinates of amino acids of a nuclear receptor coactivator binding site which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecular complex of a compound bound to a nuclear receptor coactivator binding site.
    Type: Application
    Filed: November 14, 2005
    Publication date: July 6, 2006
    Inventors: John Baxter, Beatrice Darimont, Weijun Feng, Robert Fletterick, Peter Kushner, Richard Wagner, Brian West, Keith Yamamoto
  • Inhibitors for androgen antagonist refractory prostate cancer
    Publication number: 20050202440
    Abstract: The present invention relates to methods and antagonist compounds for modulating androgen receptor activity. The invention includes a method for identifying molecules that bind to a coactivator binding site of a receptor in the androgen receptor family. Also included is a cocrystal of an androgen receptor ligand binding domain complexed with a ligand and a coactivator. The invention further includes a method for inhibiting androgen receptor activity in a mammal, thereby facilitating treatment of diseases such as prostate cancer.
    Type: Application
    Filed: November 6, 2003
    Publication date: September 15, 2005
    Inventors: Robert Fletterick, Eva Estebanez-Perpina, Eugene Hur, Samuel Pfaff, Benjamin Buehrer